Sitagliptin is supported by numerous clinical trials spanning Phase I through Phase IV evaluations across completed, active, and upcoming recruitment statuses. These studies assess the compound as both monotherapy and combination therapy for metabolic conditions—such as type 2 diabetes mellitus, type 1 diabetes, pre-diabetes, and severe obesity—as well as for pharmacokinetic assessments in healthy subjects. Research is conducted by diverse sponsors ranging from pharmaceutical corporations to academic institutions.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06813014 | NOT_YET_RECRUITING | Diabetes |
University of Maryland, Baltimore |
2026-12 | PHASE4 |
| NCT07365592 | RECRUITING | Colorectal Cancer |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2026-04-09 | PHASE1; PHASE2 |
| NCT07108985 | NOT_YET_RECRUITING | Diabetes Mellitus, Type 2; Hyperglycemia; Insulin Resistance |
Yonsei University |
2025-09 | PHASE4 |
| NCT07541781 | RECRUITING | Glioma; Glioblastoma; Recurrent Glioma; Recurrent Glioblastoma; Grade 4 Malignant Glioma of Brain (Disorder) |
Kailin Yang, MD, PhD |
2026-06-11 | PHASE1 |
| NCT06246799 | RECRUITING | Type 2 Diabetes (Adult Onset) |
The University of Texas Health Science Center at San Antonio |
2024-11-07 | PHASE3 |
| NCT07804381 | NOT_YET_RECRUITING | Parkinson Disease |
Yonsei University |
2026-12-15 | PHASE2 |
| NCT06587698 | RECRUITING | Polycystic Ovarian Syndrome |
Peking University Third Hospital |
2024-08-21 | |
| NCT07717242 | RECRUITING | Bladder Urothelial Carcinoma; Bladder Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2026-07-01 | PHASE2 |
| NCT07634380 | RECRUITING | Advanced Renal Cell Carcinoma; Advanced Melanoma |
Fernando Maciel Barbosa |
2026-05-14 | PHASE1 |
| NCT07436663 | NOT_YET_RECRUITING | Breast Cancer |
Tanta University |
2026-02-01 | PHASE4 |
| NCT07365358 | NOT_YET_RECRUITING | Diabete Type 2 |
Chong Kun Dang Pharmaceutical |
2026-03 | PHASE4 |
| NCT07003542 | RECRUITING | Glioblastoma; Brain Tumor |
Case Comprehensive Cancer Center |
2026-03-16 | PHASE2 |
| NCT07073768 | ENROLLING_BY_INVITATION | Diabetes Mellitus Type 2; Glycemic Control for Diabetes Mellitus |
Khyber Medical College, Peshawar |
2025-07-01 | PHASE3 |
| NCT05195944 | ENROLLING_BY_INVITATION | Liver Transplant; Complications; Diabetes Mellitus; NASH - Nonalcoholic Steatohepatitis; NAFLD |
University Health Network, Toronto |
2022-10-26 | PHASE4 |
| NCT07711171 | RECRUITING | Type 2 Diabetes Mellitus; Cognitive Impairment |
Fudan University |
2024-08-19 | PHASE4 |
| NCT06972732 | RECRUITING | Type 2 Diabetes |
Boryung Pharmaceutical Co., Ltd |
2025-06-11 | PHASE4 |
| NCT05947825 | ENROLLING_BY_INVITATION | PDAC - Pancreatic Ductal Adenocarcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2023-07-01 | PHASE2 |
| NCT07567781 | COMPLETED | Healthy Volunteers |
AbbVie |
2026-04-30 | PHASE1 |
| NCT06851962 | COMPLETED | Diabetes Mellitus Type 2 |
Fundación para la Investigación del Hospital Clínico de Valencia |
2025-05-26 | PHASE4 |
| NCT07374328 | RECRUITING | Type 2 Diabetes |
Second Affiliated Hospital of Guangzhou Medical University |
2025-06-01 | PHASE1; PHASE2 |
| NCT07452913 | ENROLLING_BY_INVITATION | Type 2 Diabetes Mellitus |
Bahria University |
2026-01-01 | PHASE4 |
| NCT06329882 | RECRUITING | Diabetes Mellitus, Type 2 |
Mostafa Bahaa |
2024-03-30 | PHASE1; PHASE2 |
| NCT07763964 | COMPLETED | Bioequivalance |
ADIUM |
2025-12-08 | |
| NCT07763951 | COMPLETED | Bioequivalance |
ADIUM |
2025-12-03 | |
| NCT07763912 | COMPLETED | Bioequivalence |
ADIUM |
2025-11-24 | |
| NCT05219409 | NOT_YET_RECRUITING | Type 1 Diabetes |
University of Milan |
2023-07 | PHASE2; PHASE3 |
| NCT05895201 | WITHDRAWN | Bone Marrow Transplant Complications; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia, Adult; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia |
Indiana University |
2023-11 | PHASE1; PHASE2 |
| NCT07763899 | COMPLETED | Bioequivalance |
ADIUM |
2025-11-19 | |
| NCT07531108 | COMPLETED | Diabetes Mellitus, Type 2 |
Hawler Medical University |
2024-11-15 | PHASE4 |
| NCT05833958 | WITHDRAWN | Type 2 Diabetes |
George Medicines PTY Limited |
2024-09 | PHASE2 |
| NCT07439536 | COMPLETED | Liver Cirrhosis With Diabetes |
Kafrelsheikh University |
2024-07-01 | PHASE4 |
| NCT04495881 | UNKNOWN | Type 2 Diabetes |
Beijing Chao Yang Hospital |
2020-01-01 | PHASE4 |
| NCT07172269 | COMPLETED | Diabete Mellitus; Type 2 Diabetes; Obesity Type 2 Diabetes Mellitus; Dyslipidemia in Patients With Diabetes Mellitus; Insulin Resistance |
Mais Qais Hbeeb |
2024-09-15 | |
| NCT06187285 | COMPLETED | Type 2 Diabetes |
Medanta, The Medicity, India |
2024-01-01 | |
| NCT05972928 | COMPLETED | Polycystic Ovary Syndrome |
Beni-Suef University |
2024-08-07 | PHASE2; PHASE3 |
| NCT06759922 | COMPLETED | Type 2 Diabetes Mellitus |
Bahria University |
2025-01-01 | PHASE4 |
| NCT04323189 | ACTIVE_NOT_RECRUITING | Genetics Disease; Type2 Diabetes; Heart Failure |
University of Pennsylvania |
2020-08-26 | PHASE4 |
| NCT06263673 | COMPLETED | Lewy Body Dementia; Parkinson Disease |
Mayo Clinic |
2024-05-07 | PHASE4 |
| NCT04409795 | COMPLETED | Type 1 Diabetes; Monogenic Diabetes |
Joslin Diabetes Center |
2021-08-26 | PHASE2; PHASE3 |
| NCT06147518 | UNKNOWN | Compensated Cirrhosis; Decompensated Cirrhosis |
Institute of Liver and Biliary Sciences, India |
2023-12-20 | |
| NCT05367063 | COMPLETED | Type 2 Diabetes; Cardiovascular Risk |
Shanghai Zhongshan Hospital |
2022-01-05 | PHASE4 |
| NCT06952231 | COMPLETED | Diabetes Mellitus |
University of Lahore |
2024-05-21 | PHASE3 |
| NCT05042505 | COMPLETED | Diabetes Mellitus; Liver Transplant; Complications |
Medanta, The Medicity, India |
2022-01-01 | |
| NCT03738878 | TERMINATED | Hypertension |
Vanderbilt University Medical Center |
2018-11-15 | PHASE4 |
| NCT07083232 | COMPLETED | Diabetic; Myocardial Infarction |
Al-Azhar University |
2024-10-30 | PHASE4 |
| NCT06054815 | COMPLETED | NON-ALCOHOLIC STEATOHEPATITIS |
NeuroBo Pharmaceuticals Inc. |
2023-09-14 | PHASE2 |
| NCT04271189 | COMPLETED | Newly Diagnosed Type 2 Diabetes |
Azienda Ospedaliero-Universitaria di Parma |
2020-09-01 | PHASE3 |
| NCT06515652 | UNKNOWN | Metabolic Syndrome |
Hamdard University |
2023-09-01 | |
| NCT06233201 | UNKNOWN | Healthy Subjects |
Bio-innova Co., Ltd |
2024-06-04 | PHASE1 |
| NCT06613750 | COMPLETED | Type 2 Diabetes Mellitus; Glucotoxicity |
Zhibin Xu |
2024-06-01 | PHASE4 |
| NCT06233240 | UNKNOWN | Healthy Subjects |
Bio-innova Co., Ltd |
2024-04-30 | PHASE1 |
| NCT06204107 | COMPLETED | Type 2 Diabetes Mellitus |
Chong Kun Dang Pharmaceutical |
2023-11-21 | PHASE1 |
| NCT07076056 | COMPLETED | Type 2 Diabetes |
Daewon Pharmaceutical Co., Ltd. |
2022-10-27 | PHASE3 |
| NCT04304261 | COMPLETED | Diabetes Mellitus, Type 2; Cognitive Functions Confusion |
Third Military Medical University |
2021-07-01 | PHASE3 |
| NCT05386186 | UNKNOWN | Diabetes Mellitus, Type 2; Severe Insulin Deficient Diabetes |
Peking University People's Hospital |
2022-01-01 | PHASE4 |
| NCT05667220 | UNKNOWN | Type 2 Diabetes |
Beijing Chao Yang Hospital |
2022-12-01 | PHASE4 |
| NCT06770894 | COMPLETED | Osteoporosis; Bone Loss, Postmenopausal; Diabetes Mellitus Type 2 |
Azienda Policlinico Umberto I |
2019-09-24 | PHASE3 |
| NCT02879409 | ACTIVE_NOT_RECRUITING | Diabetes Mellitus Type 2 |
Weill Cornell Medical College in Qatar |
2016-11 | |
| NCT05149365 | COMPLETED | Acute-graft-versus-host Disease; Allogeneic Hematopoietic Stem Cell Transplantation |
The First Affiliated Hospital of Soochow University |
2021-12-22 | PHASE3 |
| NCT05579119 | COMPLETED | Type 2 Diabetes |
Hospital de Especialidades, Centro Medico Nacional "La Raza", Instituto Mexicano del Seguro Social |
2022-07-06 | PHASE4 |
| NCT05219409 | Not yet recruiting | Type 1 Diabetes |
University of Milan |
2023-07 | Phase 2|Phase 3 |
| NCT06115460 | COMPLETED | Type 1 Diabetic Nephropathy |
Ain Shams University |
2022-03-01 | PHASE3 |
| NCT05900531 | COMPLETED | Obesity |
Kallyope Inc. |
2022-09-21 | PHASE1 |
| NCT07679711 | COMPLETED | Healthy Volunteers |
The Affiliated Hospital of Qingdao University |
2023-02-14 | PHASE1 |
| NCT06124547 | COMPLETED | Bioequivalence; Diabetes Mellitus, Type 2 |
Galenicum Health |
2023-01-16 | PHASE1 |
| NCT06124495 | COMPLETED | Bioequivalence; Diabetes Mellitus, Type 2 |
Galenicum Health |
2023-01-13 | PHASE1 |
| NCT05798715 | COMPLETED | Healthy |
Genuine Research Center, Egypt |
2022-11-29 | PHASE1 |
| NCT05353673 | UNKNOWN | Immune Thrombocytopenia; Blood Coagulation Disorders; Thrombocytopenia; Physiological Effects of Drugs |
Peking University People's Hospital |
2021-06-01 | PHASE2 |
| NCT06124573 | COMPLETED | Bioequivalence; Diabetes Mellitus, Type 2 |
Galenicum Health |
2022-11-07 | PHASE1 |
| NCT04982705 | UNKNOWN | Type 2 Diabetes |
IlDong Pharmaceutical Co Ltd |
2021-07-07 | PHASE1 |
| NCT06124560 | COMPLETED | Bioequivalence; Diabetes Mellitus, Type 2 |
Galenicum Health |
2022-10-28 | PHASE1 |
| NCT03076112 | COMPLETED | Type 2 Diabetes Mellitus |
Seoul National University Bundang Hospital |
2017-04-25 | PHASE3 |
| NCT04161430 | COMPLETED | Type 2 Diabetes Mellitus |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2020-01-02 | PHASE3 |
| NCT05266404 | COMPLETED | Healthy Volunteers (Intended Indication: Type 2 Diabetes Mellitus) |
AstraZeneca |
2022-03-21 | PHASE1 |
| NCT05167513 | COMPLETED | Quality of Life; Type 2 Diabetes; Metformin+Sitagliptin |
Getz Pharma |
2021-01-01 | PHASE4 |
| NCT04365517 | UNKNOWN | Covid19; Diabetes Mellitus, Type 2; CKD |
University of Milan |
2021-12-29 | PHASE3 |
| NCT04298684 | UNKNOWN | Diabetes Mellitus, Type 2; Thyroid Nodule (Benign) |
Centre Hospitalier Universitaire de la Guadeloupe |
2021-01-01 | PHASE4 |
| NCT02315287 | UNKNOWN | Type 2 Diabetes |
Seoul National University Bundang Hospital |
2014-09 | PHASE4 |
| NCT04448587 | UNKNOWN | Graft Vs Host Disease |
Rabin Medical Center |
2020-10-01 | PHASE2 |
| NCT05236998 | COMPLETED | Healthy Subjects |
SK Chemicals Co., Ltd. |
2021-11-03 | PHASE1 |
| NCT02338921 | COMPLETED | Type 2 Diabetes |
Seoul National University Bundang Hospital |
2015-01 | PHASE4 |
| NCT05403281 | Completed | Healthy Subjects |
Dong Wha Pharmaceutical Co. Ltd. |
2021-11-05 | Phase 1 |
| NCT04017832 | COMPLETED | Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2019-07-29 | PHASE3 |
| NCT05359341 | COMPLETED | Diabete Type 2 |
Sadat City University |
2020-09-20 | |
| NCT02697253 | WITHDRAWN | Obesity |
Icahn School of Medicine at Mount Sinai |
2016-01 | PHASE2 |
| NCT04268563 | UNKNOWN | Polycystic Ovary Syndrome; Infertility; ART |
Shahid Beheshti University of Medical Sciences |
2020-01-10 | PHASE1; PHASE2 |
| NCT03101930 | COMPLETED | Obesity; PreDiabetes |
Vanderbilt University Medical Center |
2017-05-01 | PHASE4 |
| NCT05035849 | COMPLETED | Type 2 Diabetes |
Nanjing First Hospital, Nanjing Medical University |
2020-01-30 | |
| NCT01794143 | COMPLETED | Type 2 Diabetes; Comparative Effectiveness of Glycemia-lowering Medications |
GRADE Study Group |
2013-05 | PHASE3 |
| NCT04287387 | UNKNOWN | Type2 Diabetes Mellitus |
Peking Union Medical College Hospital |
2020-03-02 | PHASE4 |
| NCT03893526 | COMPLETED | Type2 Diabetes |
University of Copenhagen |
2019-01-25 | PHASE4 |
| NCT04801199 | COMPLETED | Uncontrolled Type 2 Diabetes Mellitus |
Cadila Pharnmaceuticals |
2020-01-26 | PHASE3 |
| NCT02653209 | COMPLETED | Type 2 Diabetes |
Royal Devon and Exeter NHS Foundation Trust |
2016-11-01 | PHASE4 |
| NCT04810507 | COMPLETED | Type 2 Diabetes |
JW Pharmaceutical |
2018-11-09 | PHASE4 |
| NCT04916093 | COMPLETED | Diabetes Mellitus, Type 2 |
Beni-Suef University |
2019-12-20 | PHASE4 |
| NCT01928199 | COMPLETED | Posttransplant Diabetes Mellitus |
Washington University School of Medicine |
2013-09 | PHASE4 |
| NCT03646721 | COMPLETED | Diabetes Mellitus, Type 2 |
Dong-A ST Co., Ltd. |
2018-08-29 | PHASE1 |
| NCT02130687 | COMPLETED | Type 2 Diabetes Mellitus; Hypertension |
Vanderbilt University |
2014-06 | |
| NCT02377388 | COMPLETED | Platelet Aggregation During Acute Myocardial Infarction |
University of Sao Paulo General Hospital |
2017-02-07 | PHASE3 |
| NCT03659461 | COMPLETED | Type 2 Diabetes Mellitus; PreDiabetes |
National University of Malaysia |
2017-10-01 | |
| NCT01879228 | COMPLETED | Cystic Fibrosis; Pancreatic Insufficiency |
University of Pennsylvania |
2013-06 | |
| NCT00813228 | COMPLETED | Diabetes Mellitus Type 1; Diabetes Mellitus Type 2 |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2009-01-06 | PHASE1 |
| NCT01485614 | COMPLETED | Diabetes Mellitus; Type 2 Diabetes |
Merck Sharp & Dohme LLC |
2012-02-10 | PHASE3 |
| NCT01760447 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2011-12-07 | PHASE3 |
| NCT03790839 | COMPLETED | Patients |
Hua Medicine Limited |
2019-01-31 | PHASE1 |
| NCT02917031 | COMPLETED | Type 2 Diabetes Mellitus; Heart Failure |
AstraZeneca |
2017-01-10 | PHASE4 |
| NCT04061473 | COMPLETED | Diabetes After Total Pancreatectomy |
University Hospital, Gentofte, Copenhagen |
2019-04-02 | |
| NCT03208465 | COMPLETED | Diabetes Mellitus; Coronary Disease |
CHEOL WHAN LEE, M.D., Ph.D |
2017-08-07 | PHASE4 |
| NCT02122380 | COMPLETED | Polycystic Ovary Syndrome |
Vanderbilt University |
2016-02 | PHASE4 |
| NCT03359590 | COMPLETED | Pharmacological Action |
Profil Institut für Stoffwechselforschung GmbH |
2018-03-21 | PHASE2 |
| NCT02802644 | UNKNOWN | Acute Coronary Syndrome; Diabetes Mellitus, Type 2 |
Chung-Ang University |
2016-06 | PHASE4 |
| NCT03602638 | UNKNOWN | Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1 |
Chinese PLA General Hospital |
2018-10-01 | PHASE4 |
| NCT03061214 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2017-08-28 | PHASE3 |
| NCT02683525 | COMPLETED | Graft vs Host Disease; Hematopoietic Stem Cell Transplantation |
Sherif S. Farag |
2016-02-03 | PHASE2 |
| NCT03717688 | COMPLETED | Diabetes; Heart Failure |
Nicolai Jacob Wewer Albrechtsen |
2018-05-17 | PHASE4 |
| NCT03790839 | Completed | Patients |
Hua Medicine Limited |
2019-01-31 | Phase 1 |
| NCT01471808 | COMPLETED | Diabetes Mellitus, Type 2 |
Sun Yat-sen University |
2011-10 | PHASE4 |
| NCT02556918 | COMPLETED | Hyperglycemia |
Emory University |
2016-01 | PHASE4 |
| NCT01140438 | COMPLETED | Diabetes |
Norwegian University of Science and Technology |
2009-03 | |
| NCT03115112 | COMPLETED | Type 2 Diabetes Mellitus |
Theracos |
2017-10-12 | PHASE3 |
| NCT03267576 | COMPLETED | Diabetes Mellitus, Type 2 |
Janssen Research & Development, LLC |
2017-10-27 | PHASE4 |
| NCT02940184 | UNKNOWN | Physiology |
University of Copenhagen |
2016-06 | |
| NCT02623998 | COMPLETED | Type 2 Diabetes Mellitus |
Population Health Research Institute |
2016-07-09 | PHASE3 |
| NCT02650427 | COMPLETED | Hepato Carcinoma |
Institut National de la Santé Et de la Recherche Médicale, France |
2016-02 | PHASE1 |
| NCT02920918 | COMPLETED | Heart Failure, Systolic; Diabetes Mellitus, Type 2 |
Virginia Commonwealth University |
2016-10 | PHASE4 |
| NCT02689362 | COMPLETED | Diabetes Mellitus, Type 2 |
Eurofarma Laboratorios S.A. |
2017-08-08 | PHASE2 |
| NCT01951339 | COMPLETED | Type 2 Diabetes; Cardiovascular Disease |
University of Colorado, Denver |
2013-10 | |
| NCT04877106 | COMPLETED | Healthy Subjects |
The Affiliated Hospital of Qingdao University |
2018-04-07 | PHASE1 |
| NCT02882477 | UNKNOWN | Diabetes Mellitus; Iron Metabolism Disorders; Gastroduodenal Ulcer; Optic Atrophy; Sensorineural Hearing Loss; Platelet Dysfunction |
Hadassah Medical Organization |
2016-12 | PHASE2; PHASE3 |
| NCT05549583 | COMPLETED | Bioequivalence; Type 2 Diabetes |
Galenicum Health |
2018-04-15 | PHASE1 |
| NCT03115099 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2017-05-31 | PHASE1 |
| NCT02683187 | COMPLETED | Healthy |
David D'Alessio, M.D. |
2017-03-01 | PHASE1 |
| NCT03359590 | Completed | Pharmacological Action |
Profil Institut für Stoffwechselforschung GmbH|Merck Sharp & Dohme LLC |
2018-03-21 | Phase 2 |
| NCT02849080 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-09-20 | PHASE3 |
| NCT02060383 | COMPLETED | Cushing's Disease; Acromegaly |
Novartis Pharmaceuticals |
2014-05-23 | PHASE4 |
| NCT02791490 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2016-06-16 | PHASE3 |
| NCT02738879 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2016-05-09 | PHASE3 |
| NCT03108521 | COMPLETED | Diabetes Mellitus |
Sichuan Provincial People's Hospital |
2016-04-21 | PHASE4 |
| NCT02330406 | COMPLETED | Dipeptidyl-Peptidase 4 Inhibitors; LDL Cholesterol; Glycosylated Hemoglobin; Diabetes Mellitus; Coronary Disease |
Institute for Clinical Effectiveness, Japan |
2015-04 | PHASE4 |
| NCT02576288 | COMPLETED | Atherosclerosis; Inflammation |
University of Southern California |
2016-01 | PHASE2 |
| NCT01336322 | COMPLETED | Pre-diabetes |
University of Pisa |
2011-05 | PHASE2 |
| NCT02743260 | COMPLETED | Healthy |
University of Cologne |
2016-04 | PHASE4 |
| NCT03593135 | COMPLETED | Randomized Controlled Trial; Diabetes Mellitus |
Sheikh Zayed Federal Postgraduate Medical Institute |
2017-07-15 | |
| NCT05549570 | COMPLETED | Bioequivalence; Diabetes Mellitus, Type 2 |
Galenicum Health |
2017-10-22 | PHASE1 |
| NCT02532855 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2015-10-20 | PHASE3 |
| NCT02567994 | COMPLETED | Type 2 Diabetes Mellitus |
Handok Inc. |
2015-04 | PHASE3 |
| NCT02536248 | COMPLETED | Type 2 Diabetes Mellitus |
Laval University |
2015-08-01 | PHASE3 |
| NCT01856907 | COMPLETED | Disorder of Glucose Regulation |
Woman's |
2013-09-28 | PHASE4 |
| NCT02043054 | COMPLETED | Type 2 Diabetes Mellitus; Cardiovascular Disease |
University of Leicester |
2013-12-16 | PHASE3 |
| NCT02256189 | COMPLETED | Type 2 Diabetes |
Lund University |
2015-04 | PHASE4 |
| NCT02301806 | UNKNOWN | Type 2 Diabetes |
Dokkyo Medical University |
2015-01 | PHASE4 |
| NCT02089438 | COMPLETED | Type 2 Diabetes |
Lund University |
2014-05 | PHASE4 |
| NCT02639637 | COMPLETED | Type 2 Diabetes Mellitus |
Vanderbilt University |
2015-12 | PHASE4 |
| NCT01701973 | COMPLETED | Obesity |
Vanderbilt University |
2013-01 | PHASE4 |
| NCT01999218 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2013-12-16 | PHASE3 |
| NCT02527993 | COMPLETED | Hypoglycemia; Obesity; Surgery |
Zealand University Hospital |
2015-10 | PHASE4 |
| NCT03125694 | COMPLETED | Uncontrolled Type 2 Diabetes Mellitus |
Tehran University of Medical Sciences |
2015-02-01 | PHASE3 |
| NCT02147925 | COMPLETED | Non-alcoholic Fatty Liver Disease |
Sun Yat-sen University |
2014-08 | PHASE4 |
| NCT02741687 | COMPLETED | Hyperglycemia |
Emory University |
2016-06 | PHASE4 |
| NCT00967798 | TERMINATED | Cystic Fibrosis; Prediabetes |
Emory University |
2010-05 | PHASE3 |
| NCT02564211 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2015-10-26 | PHASE3 |
| NCT02956044 | COMPLETED | Type2 Diabetes Mellitus |
Theracos |
2016-11 | PHASE1 |
| NCT02675335 | WITHDRAWN | Diabetic Foot |
Wolfgang-Michael Franz |
2016-03 | PHASE3 |
| NCT02607865 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2016-02-15 | PHASE3 |
| NCT02655757 | COMPLETED | Atherosclerosis; Type 2 Diabetes Mellitus |
Li Bo |
2015-12 | PHASE4 |
| NCT01984606 | WITHDRAWN | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2015-01 | PHASE3 |
| NCT02647320 | COMPLETED | Type 2 Diabetes Mellitus |
Daiichi Sankyo |
2016-01 | PHASE2 |
| NCT02452632 | COMPLETED | Type 2 Diabetes Mellitus |
Astellas Pharma Korea, Inc. |
2015-06-22 | PHASE3 |
| NCT02324010 | COMPLETED | Gastroparesis; Diabetes Mellitus |
Royal Adelaide Hospital |
2015-07 | PHASE2 |
| NCT02173457 | COMPLETED | Type 2 Diabetes |
Chipscreen Biosciences, Ltd. |
2014-09 | PHASE3 |
| NCT02373865 | TERMINATED | Diabetes Mellitus Type 2 |
GWT-TUD GmbH |
2015-09 | PHASE4 |
| NCT02513771 | COMPLETED | HIV-1 Infection |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections |
2015-09 | PHASE2 |
| NCT01703637 | UNKNOWN | Type 2 Diabetes Mellitus |
Lin Liao |
2012-10 | |
| NCT02347501 | COMPLETED | Psoriasis |
University College Dublin |
2013-11 | PHASE2 |
| NCT02480465 | UNKNOWN | Diabetes Mellitus, Type 2 |
Chong Kun Dang Pharmaceutical |
2015-01 | PHASE4 |
| NCT02443402 | COMPLETED | Coronary Artery Disease |
Emory University |
2016-01 | PHASE4 |
| NCT02577003 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2015-11-09 | PHASE3 |
| NCT02577016 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2015-11-05 | PHASE3 |
| NCT01824264 | WITHDRAWN | Type 2 Diabetes Mellitus |
Novartis Pharmaceuticals |
2015-11 | PHASE2 |
| NCT03122041 | COMPLETED | PCOS |
University Medical Centre Ljubljana |
2016-08 | PHASE4 |
| NCT02900417 | UNKNOWN | Type 2 Diabetes |
Second Affiliated Hospital of Soochow University |
2016-09 | |
| NCT02294084 | COMPLETED | Neoplasms, Adipose Tissue |
Ingrid Jazet |
2014-03 | PHASE4 |
| NCT02512523 | COMPLETED | Type 2 Diabetes Mellitus |
Handok Inc. |
2015-08-27 | PHASE4 |
| NCT02284893 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2014-09-09 | PHASE3 |
| NCT02363335 | COMPLETED | Healthy Volunteers |
National Institute on Aging (NIA) |
2015-02-13 | PHASE1 |
| NCT02628392 | COMPLETED | Type2 Diabetes Mellitus |
Daiichi Sankyo Co., Ltd. |
2015-11 | |
| NCT02685345 | COMPLETED | Type 2 Diabetes Mellitus |
Daiichi Sankyo Co., Ltd. |
2016-01 | PHASE2 |
| NCT01720264 | COMPLETED | Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Hematopoetic Myelodysplasia; Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin |
Sherif S. Farag |
2012-11-02 | PHASE2 |
| NCT02941445 | COMPLETED | Polycystic Ovary Syndrome; Body Weight |
University Medical Centre Ljubljana |
2015-10 | PHASE4 |
| NCT01512797 | COMPLETED | Type 2 Diabetes Mellitus |
Blandine Laferrere |
2012-07 | |
| NCT01970462 | TERMINATED | Diabetes Mellitus, Type 2; Hyperglycemia |
Kathleen Dungan |
2014-01 | PHASE4 |
| NCT02405260 | COMPLETED | Diabetes Mellitus, Type 2 |
vTv Therapeutics |
2015-03 | PHASE2 |
| NCT02127047 | COMPLETED | Diabetes Mellitus Type 1 |
University Hospital, Basel, Switzerland |
2013-11 | PHASE2 |
| NCT02036515 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2014-03-12 | PHASE3 |
| NCT01721382 | COMPLETED | Cystic Fibrosis |
Nemours Children's Clinic |
2012-11 | PHASE1 |
| NCT02099110 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2014-04-22 | PHASE3 |
| NCT02312063 | COMPLETED | Diabetes Mellitus, Type 2 |
Kansai Electric Power Hospital |
2015-02 | PHASE4 |
| NCT02336659 | COMPLETED | Severe Obesity |
Hvidovre University Hospital |
2014-04 | |
| NCT02827890 | COMPLETED | Diabetes Mellitus Type 2 |
Chong Kun Dang Pharmaceutical |
2016-04 | PHASE1 |
| NCT02824874 | COMPLETED | Diabetes Mellitus, Type II |
Chong Kun Dang Pharmaceutical |
2016-04 | PHASE1 |
| NCT01845831 | COMPLETED | Type 2 Diabetes |
Emory University |
2013-08 | PHASE4 |
| NCT02226003 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2014-09-23 | PHASE3 |
| NCT02048904 | TERMINATED | Type 2 Diabetes; Microalbuminuria |
University of Missouri-Columbia |
2014-01 | PHASE4 |
| NCT02328040 | COMPLETED | Diabetes Mellitus, Type 1 |
Albert Einstein College of Medicine |
2014-09 | PHASE1 |
| NCT01859793 | COMPLETED | Diabetes; Atherosclerosis |
Medical College of Wisconsin |
2013-06 | PHASE4 |
| NCT01963845 | COMPLETED | Non-alcoholic Fatty Liver Disease |
University of California, San Diego |
2014-01 | PHASE2 |
| NCT02444364 | WITHDRAWN | Type 2 Diabetes |
University of Missouri-Columbia |
2015-05 | EARLY_PHASE1 |
| NCT01991197 | COMPLETED | Psoriasis; Type 2 Diabetes Mellitus |
University College Dublin |
2014-04 | PHASE2 |
| NCT02318693 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2015-02-04 | PHASE4 |
| NCT05480007 | COMPLETED | NAFLD |
Shanghai 10th People's Hospital |
2011-01-30 | |
| NCT02443922 | UNKNOWN | Type 2 Diabetes |
Foundation for the National Institutes of Health |
2015-06 | |
| NCT02263677 | WITHDRAWN | Type 2 Diabetes; Non-alcoholic Fatty Liver Disease |
University of Missouri-Columbia |
2014-03 | PHASE4 |
| NCT01718093 | COMPLETED | Type 1 Diabetes |
Baylor College of Medicine |
2012-10 | PHASE4 |
| NCT01901861 | COMPLETED | Type 2 Diabetes |
Lund University |
2013-07 | |
| NCT02254291 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2014-10-02 | PHASE3 |
| NCT01073826 | COMPLETED | Diabetes Mellitus, Type 2; Obesity |
University of Zurich |
2010-02 | |
| NCT02200991 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2014-08 | PHASE4 |
| NCT01930188 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2013-12-02 | PHASE3 |
| NCT02072096 | TERMINATED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2014-02 | PHASE4 |
| NCT02025907 | COMPLETED | Diabetes Mellitus, Type 2 |
Janssen Research & Development, LLC |
2014-02 | PHASE4 |
| NCT02111096 | TERMINATED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2014-04 | PHASE2 |
| NCT01744236 | COMPLETED | Type 2 Diabetes |
Amsterdam UMC, location VUmc |
2013-04 | PHASE4 |
| NCT00964184 | COMPLETED | Diabetes Mellitus, Type 2 |
Diabetes Foundation, India |
2009-09 | PHASE4 |
| NCT01863147 | COMPLETED | Newly Diagnosed Type 2 Diabetes; Coronary Artery Disease |
Wuhan General Hospital of Guangzhou Military Command |
2013-07 | PHASE4 |
| NCT01186562 | COMPLETED | Pancreatitis; Diabetes |
University of Minnesota |
2010-08 | PHASE4 |
| NCT01455870 | COMPLETED | Type 2 Diabetes |
Intarcia Therapeutics |
2013-05 | PHASE3 |
| NCT02493959 | COMPLETED | Healthy |
Hvidovre University Hospital |
2014-05 | EARLY_PHASE1 |
| NCT01907854 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2013-12-02 | PHASE4 |
| NCT02406950 | UNKNOWN | Healthy |
Kyunghee University Medical Center |
2015-02 | PHASE3 |
| NCT02250794 | WITHDRAWN | Type 2 Diabetes Mellitus |
Rush University Medical Center |
2014-10 | PHASE4 |
| NCT01709305 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2012-11-08 | PHASE4 |
| NCT01260246 | TERMINATED | Type 2 Diabetes; Nonalcoholic Steatohepatitis |
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
2010-12 | |
| NCT00790205 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2008-12-10 | PHASE3 |
| NCT01530178 | COMPLETED | Diabetes Mellitus, Type 1 |
Albert Einstein College of Medicine |
2011-11 | PHASE4 |
| NCT02386943 | UNKNOWN | Type 2 Diabetes |
Shanghai Jiao Tong University School of Medicine |
2013-12 | PHASE4 |
| NCT01847144 | COMPLETED | Type 2 Diabetes |
Royal Devon and Exeter NHS Foundation Trust |
2013-04 | PHASE4 |
| NCT02202161 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2014-08-27 | PHASE2 |
| NCT02015910 | TERMINATED | Type II Diabetes |
Georgetown University |
2014-01 | PHASE4 |
| NCT01183104 | COMPLETED | Type 2 Diabetes |
Japan Association for Diabetes Education and Care |
2010-08 | |
| NCT01841697 | COMPLETED | Type 2 Diabetes |
Merck Sharp & Dohme LLC |
2013-06-13 | PHASE3 |
| NCT02949193 | COMPLETED | Type 2 Diabetes Mellitus |
Dong-A ST Co., Ltd. |
2013-05 | PHASE3 |
| NCT02008682 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2013-12 | PHASE4 |
| NCT01552694 | COMPLETED | Inflammation; Macrophage Infiltration; Cardiovascular Disease |
Washington University School of Medicine |
2012-10 | PHASE3 |
| NCT01686932 | COMPLETED | Diabetes Mellitus Type 2 |
Novartis Pharmaceuticals |
2012-11 | PHASE4 |
| NCT01449747 | COMPLETED | Type 2 Diabetes Mellitus |
The Catholic University of Korea |
2011-12 | PHASE4 |
| NCT01890629 | COMPLETED | Type 2 Diabetes Mellitus |
LG Life Sciences |
2013-05 | PHASE4 |
| NCT01610154 | COMPLETED | Insulin Secretion; Insulin Resistance |
Guangwei Li |
2012-10 | PHASE4 |
| NCT01488279 | COMPLETED | Pre-diabetes; Impaired Fasting Glucose; Impaired Glucose Tolerance |
University of Vermont |
2012-09 | |
| NCT01455909 | WITHDRAWN | Type 2 Diabetes |
Intarcia Therapeutics |
2013-02 | PHASE3 |
| NCT01590797 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2012-07-10 | PHASE3 |
| NCT01590771 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2012-07-09 | PHASE3 |
| NCT01895569 | UNKNOWN | Type 2 Diabetes Mellitus |
University of Pavia |
2013-06 | PHASE4 |
| NCT01155284 | COMPLETED | Type 1 Diabetes |
Sanford Health |
2010-08 | PHASE2 |
| NCT01341717 | COMPLETED | Diabetes Mellitus, Type 2 |
Jothydev's Diabetes and Research Centre |
2012-02 | PHASE4 |
| NCT01557504 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2012-07-18 | PHASE1 |
| NCT01703221 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2012-10-24 | PHASE3 |
| NCT01936025 | COMPLETED | Type 2 Diabetes Mellitus |
Profil Institut für Stoffwechselforschung GmbH |
2013-10 | PHASE2 |
| NCT01937598 | COMPLETED | Type 2 Diabetes |
Michael A. Nauck |
2013-08 | PHASE3 |
| NCT01652729 | COMPLETED | Diabetes Type 2 |
AstraZeneca |
2013-02 | PHASE3 |
| NCT01785043 | COMPLETED | DIABETES Mellitus Type 2 Not Well Controlled |
Anna Cruceta |
2013-03 | PHASE4 |
| NCT02749032 | COMPLETED | Type 2 Diabetes |
Michael A. Nauck |
2011-11 | PHASE1 |
| NCT01834274 | TERMINATED | Diabetes Mellitus, Type 2 |
Takeda |
2013-06 | PHASE3 |
| NCT01549964 | TERMINATED | Glycemic Control |
Takeda |
2012-04 | PHASE3 |
| NCT01099618 | COMPLETED | Ketosis Prone Diabetes; Diabetes Ketoacidosis; Hyperglycemia |
Dawn Smiley MD |
2010-03 | PHASE4 |
| NCT02192853 | COMPLETED | Type 2 Diabetes Mellitus |
University Hospital, Gentofte, Copenhagen |
2013-05 | PHASE4 |
| NCT01038648 | WITHDRAWN | Type 2 Diabetes |
India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals |
2011-12 | PHASE3 |
| NCT01829464 | TERMINATED | Diabetes |
Takeda |
2013-05 | PHASE3 |
| NCT01567540 | TERMINATED | Hepatitis C |
Institut National de la Santé Et de la Recherche Médicale, France |
2013-03 | PHASE1 |
| NCT00659711 | COMPLETED | Type 2 Diabetes |
University at Buffalo |
2008-03 | |
| NCT01717911 | UNKNOWN | Type 2 Diabetes |
Taipei Veterans General Hospital, Taiwan |
2010-09 | PHASE4 |
| NCT01678820 | TERMINATED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2012-10-10 | PHASE3 |
| NCT00853944 | TERMINATED | Islet Transplantation |
University of British Columbia |
2009-07 | PHASE3 |
| NCT00993187 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2010-05-04 | PHASE4 |
| NCT01519674 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2012-06 | PHASE4 |
| NCT01741103 | WITHDRAWN | Diabetes Type I |
University at Buffalo |
2011-06 | |
| NCT01619332 | COMPLETED | Type II Diabetes |
Novartis Pharmaceuticals |
2012-03 | PHASE1; PHASE2 |
| NCT01751321 | UNKNOWN | Type 2 Diabetes |
Research Clinical Centre of the Russian Railways, JSC |
2013-05 | |
| NCT01413542 | COMPLETED | Hypertension; Diabetes Type 2 |
Vanderbilt University |
2011-11 | |
| NCT01462266 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2012-01-13 | PHASE3 |
| NCT01702298 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2012-12-07 | PHASE3 |
| NCT01529541 | COMPLETED | Type 2 Diabetes Mellitus |
JW Pharmaceutical |
2011-05 | PHASE3 |
| NCT01642108 | UNKNOWN | Type 2 Diabetes |
Niigata Medical Center |
2012-07 | |
| NCT01600703 | COMPLETED | Hyperlipidemia |
University Health Network, Toronto |
2012-07 | PHASE2; PHASE3 |
| NCT01820104 | COMPLETED | Healthy |
Xijing Hospital |
2013-03 | PHASE1 |
| NCT01289990 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2011-02 | PHASE3 |
| NCT01177384 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2011-01-25 | PHASE3 |
| NCT01545388 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2012-02-23 | PHASE3 |
| NCT01334229 | COMPLETED | Type 2 Diabetes Mellitus |
Laval University |
2011-04 | PHASE3 |
| NCT01337440 | UNKNOWN | Type 2 Diabetes Mellitus; Chronic Liver Disease |
Kanazawa University |
2010-04 | PHASE4 |
| NCT01475461 | COMPLETED | Type 2 Diabetes Mellitus |
Pfizer |
2011-11 | PHASE2 |
| NCT01076088 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2010-11-15 | PHASE3 |
| NCT01582308 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2012-06-21 | PHASE1 |
| NCT01477853 | TERMINATED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2011-10-24 | PHASE3 |
| NCT01660386 | UNKNOWN | Type 2 Diabetes |
Shanghai Jiao Tong University School of Medicine |
2012-07 | PHASE4 |
| NCT00683735 | COMPLETED | Diabetes |
Michael A. Nauck |
2009-02 | PHASE2; PHASE3 |
| NCT00775684 | COMPLETED | Pre-diabetes; Type 2 Diabetes |
University of Pennsylvania |
2008-10 | |
| NCT00862719 | COMPLETED | Leukemia, Myeloid, Acute; Acute Lymphoblastic Leukemia; Myelodysplasia; Leukemia, Myelogenous, Chronic; Lymphoma, Non-Hodgkin |
Indiana University |
2009-03 | PHASE2 |
| NCT00451113 | COMPLETED | Type 2 Diabetes |
University of British Columbia |
2006-11 | PHASE2 |
| NCT01098539 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2010-05 | PHASE3 |
| NCT01189890 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2010-08-16 | PHASE3 |
| NCT01376323 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2011-07-13 | PHASE2 |
| NCT01414920 | COMPLETED | Diabetes Mellitus, Type 2 |
Takeda |
2011-08 | PHASE2 |
| NCT01374568 | TERMINATED | Type 2 Diabetes Mellitus |
University of Alabama at Birmingham |
2010-07 | PHASE4 |
| NCT01159847 | COMPLETED | Type 1 Diabetes |
European Foundation for the Study of Diabetes |
2010-01 | PHASE1; PHASE2 |
| NCT00721552 | COMPLETED | Diabetes Mellitus; Steroid Diabetes; Glucocorticoid-induced Diabetes; Beta-cell Function |
Amsterdam UMC, location VUmc |
2008-10 | |
| NCT01272583 | COMPLETED | Type 1 Diabetes; Hypoglycemia |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2011-03 | |
| NCT00740363 | COMPLETED | Glucose Intolerance |
University of Oslo School of Pharmacy |
2008-09 | PHASE4 |
| NCT01398592 | COMPLETED | Diabetes Mellitus Type 2 |
Novartis Pharmaceuticals |
2011-06 | PHASE4 |
| NCT00650143 | COMPLETED | Acute Myocardial Infarction |
Ludwig-Maximilians - University of Munich |
2008-03 | PHASE2; PHASE3 |
| NCT01257464 | TERMINATED | Cystic Fibrosis |
University of British Columbia |
2010-09 | PHASE2 |
| NCT00820573 | COMPLETED | Diabetes |
The University of Texas Health Science Center at San Antonio |
2009-10 | PHASE4 |
| NCT01378117 | COMPLETED | Type 2 Diabetes Mellitus; Hospitalization; Hyperglycemia |
Emory University |
2011-08 | PHASE4 |
| NCT01405911 | COMPLETED | Glucose Intolerance |
Merck Sharp & Dohme LLC |
2011-08-16 | PHASE2 |
| NCT01408888 | COMPLETED | Diabetes Mellitus, Type 2 |
Eli Lilly and Company |
2011-08 | PHASE1 |
| NCT01177813 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2010-07 | PHASE3 |
| NCT01338870 | COMPLETED | Diabetes Mellitus, Type 2 |
Pfizer |
2011-06 | PHASE2 |
| NCT01137812 | COMPLETED | Diabetes Mellitus, Type 2 |
Janssen Research & Development, LLC |
2010-07 | PHASE3 |
| NCT01336738 | COMPLETED | Diabetes, Type 2 |
Pfizer |
2011-06 | PHASE2 |
| NCT01296412 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2011-03-11 | PHASE3 |
| NCT00838903 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2009-02 | PHASE3 |
| NCT01100125 | COMPLETED | Diabetes |
Seoul National University Bundang Hospital |
2010-04 | PHASE4 |
| NCT02607410 | COMPLETED | Type 2 Diabetes Mellitus |
University of Sao Paulo General Hospital |
2010-01 | PHASE4 |
| NCT01006018 | TERMINATED | Prediabetic State |
Emory University |
2011-07 | |
| NCT00673894 | COMPLETED | Type 2 Diabetes |
Garvan Institute of Medical Research |
2008-04 | |
| NCT01106690 | COMPLETED | Diabetes Mellitus, Type 2 |
Janssen Research & Development, LLC |
2010-06 | PHASE3 |
| NCT01096277 | UNKNOWN | Type 2 Diabetes Mellitus |
Hannover Medical School |
2010-10 | PHASE4 |
| NCT01441232 | COMPLETED | Type 2 Diabetes Mellitus |
Lexicon Pharmaceuticals |
2011-10 | PHASE1 |
| NCT01106677 | COMPLETED | Diabetes Mellitus, Type 2 |
Janssen Research & Development, LLC |
2010-05 | PHASE3 |
| NCT00998686 | TERMINATED | Type 2 Diabetes Mellitus |
Phenomix |
2009-11 | PHASE3 |
| NCT01195090 | COMPLETED | Type 2 Diabetes |
Sung-Chen Liu |
2009-10 | PHASE4 |
| NCT01340768 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2010-06-22 | PHASE3 |
| NCT01624116 | COMPLETED | Diabetes, Type 2 |
Services Hospital, Lahore |
2011-08 | |
| NCT01235819 | COMPLETED | Type 1 Diabetes |
Command Hospital, India |
2010-11 | PHASE4 |
| NCT00958269 | TERMINATED | Type 2 Diabetes Mellitus; Renal Impairment |
Phenomix |
2009-08 | PHASE3 |
| NCT00851903 | COMPLETED | Diabetes Mellitus, Type 2 |
Sanofi |
2009-06 | PHASE3 |
| NCT01081834 | COMPLETED | Diabetes Mellitus, Type 2 |
Janssen Research & Development, LLC |
2010-03 | PHASE3 |
| NCT01076075 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2010-06-03 | PHASE3 |
| NCT01092663 | COMPLETED | Diabetes Mellitus, Type 2 |
KineMed |
2010-03 | |
| NCT01112670 | COMPLETED | Healthy |
University of Colorado, Denver |
2009-11 | PHASE4 |
| NCT01169090 | COMPLETED | Type 2 Diabetes |
Kowa Research Institute, Inc. |
2010-07 | PHASE2 |
| NCT00751114 | COMPLETED | Diabetes Mellitus, Type 2 |
Sanofi |
2008-11 | PHASE4 |
| NCT00768651 | COMPLETED | Type 1 Diabetes |
University of Alberta |
2008-10 | PHASE2 |
| NCT01193296 | COMPLETED | Type 2 Diabetes Mellitus |
Novartis |
2010-06 | PHASE4 |
| NCT01093651 | COMPLETED | Diabetes; Insulin Resistance |
Washington University School of Medicine |
2010-06 | PHASE2; PHASE3 |
| NCT01602003 | COMPLETED | Type 2 Diabetes Mellitus |
LG Life Sciences |
2009-12 | PHASE3 |
| NCT00961363 | UNKNOWN | Impaired Glucose Tolerance |
National Taiwan University Hospital |
2009-12 | PHASE2 |
| NCT00881530 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2009-03 | PHASE2 |
| NCT00885638 | COMPLETED | Healthy; Type 2 Diabetes |
Lund University |
2009-08 | PHASE4 |
| NCT00939939 | TERMINATED | Diabetes Mellitus Type 2 |
Ludwig-Maximilians - University of Munich |
2010-03 | PHASE4 |
| NCT00770081 | COMPLETED | Diabetes Mellitus, Type 2; Renal Insufficiency |
Novartis |
2008-09 | PHASE3 |
| NCT01422590 | COMPLETED | Type 2 Diabetes Mellitus |
Samsung Medical Center |
2010-05 | PHASE1 |
| NCT00509262 | COMPLETED | Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic |
Merck Sharp & Dohme LLC |
2007-10-09 | PHASE3 |
| NCT00509236 | COMPLETED | Diabetes Mellitus, Type 2; End-Stage Kidney Disease |
Merck Sharp & Dohme LLC |
2007-10-19 | PHASE3 |
| NCT00860288 | COMPLETED | Diabetes Mellitus, Type 2 |
Novartis Pharmaceuticals |
2009-02 | PHASE2; PHASE3 |
| NCT00984867 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2009-10 | PHASE3 |
| NCT00976937 | COMPLETED | Type 2 Diabetes Mellitus |
Sanofi |
2009-08 | PHASE3 |
| NCT00837759 | TERMINATED | Diabetes Mellitus Type 1; Autoimmune Diabetes |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2009-02 | PHASE2 |
| NCT00754988 | COMPLETED | Diabetes Mellitus Type 2 |
Hoffmann-La Roche |
2008-10 | PHASE3 |
| NCT00657280 | COMPLETED | Heart Failure, Congestive |
Stanford University |
2008-04 | EARLY_PHASE1 |
| NCT01059825 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2010-02-24 | PHASE2 |
| NCT00466518 | COMPLETED | Kidney Transplant; Type 2 Diabetes |
University of Oklahoma |
2007-04 | |
| NCT00730275 | COMPLETED | Type 2 Diabetes |
Merck Sharp & Dohme LLC |
2008-07-18 | PHASE1 |
| NCT00847080 | COMPLETED | Reactive Hypoglycemia |
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
2008-12 | PHASE4 |
| NCT00885352 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2009-04-15 | PHASE3 |
| NCT01131182 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
Merck Sharp & Dohme LLC |
2010-06-13 | PHASE4 |
| NCT00627744 | COMPLETED | Myocardial Infarction; Unstable Angina Pectoris; Diabetes Mellitus; Impaired Glucose Tolerance |
Karolinska Institutet |
2008-05 | PHASE4 |
| NCT01046110 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2010-01 | PHASE3 |
| NCT00722371 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2008-09-05 | PHASE3 |
| NCT01034111 | COMPLETED | Type 2 Diabetes |
Merck Sharp & Dohme LLC |
2010-03-01 | PHASE3 |
| NCT00957060 | COMPLETED | Diabetes Mellitus, Type 2 |
Sanofi |
2009-07 | PHASE4 |
| NCT00616811 | COMPLETED | Diabetes Mellitus, Type 2 |
Novartis |
2008-01 | PHASE3 |
| NCT00976261 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2009-10-17 | PHASE1 |
| NCT00747383 | COMPLETED | Type 2 Diabetes Mellitus |
The Royal Bournemouth Hospital |
2008-09 | |
| NCT00837577 | COMPLETED | Diabetes Mellitus, Non-Insulin-Dependent |
Merck Sharp & Dohme LLC |
2009-02-05 | PHASE3 |
| NCT00813995 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2008-12-09 | PHASE3 |
| NCT01089790 | TERMINATED | Diabetes Mellitus, Type 2 |
Forest Laboratories |
2010-03 | PHASE3 |
| NCT01035879 | COMPLETED | Diabetes |
Gilead Sciences |
2009-12 | PHASE2 |
| NCT00676338 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2008-11 | PHASE3 |
| NCT01093794 | COMPLETED | Type 2 Diabetes |
Merck Sharp & Dohme LLC |
2010-04 | PHASE1 |
| NCT00901979 | COMPLETED | Type 2 Diabetes Mellitus |
Novartis Pharmaceuticals |
2009-04 | PHASE2 |
| NCT00732121 | UNKNOWN | Type 2 Diabetes |
University of Vermont |
2008-08 | PHASE4 |
| NCT00699322 | UNKNOWN | Type 2 Diabetes |
The Catholic University of Korea |
2008-06 | PHASE4 |
| NCT00969566 | COMPLETED | Diabetes |
Seoul National University Bundang Hospital |
2009-01 | PHASE4 |
| NCT00855166 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-02 | PHASE3 |
| NCT00936663 | TERMINATED | Type 2 Diabetes; End Stage Renal Disease |
University of Nebraska |
2009-07-06 | PHASE4 |
| NCT01095991 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2010-03 | PHASE1 |
| NCT00704132 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
Merck Sharp & Dohme LLC |
2007-02-14 | PHASE1 |
| NCT01128621 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2009-11-23 | PHASE2 |
| NCT00870194 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-03 | PHASE4 |
| NCT01119846 | COMPLETED | Diabetes Mellitus, Type 2 |
GlaxoSmithKline |
2009-06-05 | PHASE2 |
| NCT00686634 | COMPLETED | Type 2 Diabetes Mellitus |
Charles Drew University of Medicine and Science |
2008-01 | PHASE4 |
| NCT01104532 | COMPLETED | Healthy; Pharmacokinetics of ASP1941 |
Astellas Pharma Inc |
2010-02 | PHASE1 |
| NCT00541450 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2008-01-15 | PHASE3 |
| NCT00978796 | COMPLETED | Type 1 Diabetes |
University of Colorado, Denver |
2009-09 | PHASE4 |
| NCT00968006 | COMPLETED | Type 2 Diabetes Mellitus |
University of Padova |
2009-10 | PHASE4 |
| NCT00545584 | COMPLETED | Diabetes Mellitus, Non-Insulin-Dependent |
Merck Sharp & Dohme LLC |
2007-04-01 | PHASE3 |
| NCT00833027 | COMPLETED | Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2008-03-01 | PHASE4 |
| NCT00532935 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2008-01-26 | PHASE3 |
| NCT00749190 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2008-08 | PHASE2 |
| NCT00766441 | TERMINATED | Diabetes; Hypoglycemia |
University of Manchester |
2008-08 | PHASE4 |
| NCT00780715 | COMPLETED | Diabetes Mellitus, Type 2 |
University of Dundee |
2008-12 | PHASE4 |
| NCT00729326 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2008-08 | PHASE4 |
| NCT00701090 | COMPLETED | Type 2 Diabetes Mellitus, Non Insulin Dependent; Diabetes Mellitus, Non-Insulin-Dependent |
Merck Sharp & Dohme LLC |
2008-05 | PHASE3 |
| NCT00832624 | TERMINATED | Diabetes Mellitus Non-insulin-dependent |
Merck Sharp & Dohme LLC |
2008-11-26 | PHASE4 |
| NCT00960453 | COMPLETED | Diabetes Mellitus |
Seoul National University Hospital |
2008-12 | PHASE1 |
| NCT00420511 | COMPLETED | Type 2 Diabetes Mellitus |
Samuel Lunenfeld Research Institute, Mount Sinai Hospital |
2007-01 | PHASE2 |
| NCT00789191 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2008-11 | PHASE3 |
| NCT00666848 | COMPLETED | Metabolic Syndrome; Hypertension |
Vanderbilt University |
2008-03 | PHASE4 |
| NCT00871507 | COMPLETED | Diabetes Mellitus, Type 2 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2009-04 | PHASE1 |
| NCT00425490 | COMPLETED | Diabetes Mellitus Type 2 |
Sheba Medical Center |
2007-01 | PHASE3 |
| NCT02172196 | COMPLETED | Healthy |
Boehringer Ingelheim |
2009-05 | PHASE1 |
| NCT00888238 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2009-05-12 | PHASE1 |
| NCT00696982 | UNKNOWN | Diabetes Mellitus; Arterial Stiffness |
Assaf-Harofeh Medical Center |
2008-06 | |
| NCT00700817 | COMPLETED | Diabetes; Diabetes Mellitus, Type 2 |
Novo Nordisk A/S |
2008-06 | PHASE3 |
| NCT00842556 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2009-03 | PHASE1 |
| NCT00783549 | COMPLETED | Dyslipidaemias |
GlaxoSmithKline |
2008-09-04 | PHASE1 |
| NCT00666458 | COMPLETED | Type 2 Diabetes |
AstraZeneca |
2008-04 | PHASE3 |
| NCT00511108 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
Merck Sharp & Dohme LLC |
2007-07-11 | PHASE1 |
| NCT00637273 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2008-01 | PHASE3 |
| NCT01028391 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2007-09-01 | PHASE3 |
| NCT00660075 | COMPLETED | Diabetes Mellitus; Postprandial Lipemia |
Laval University |
2008-02 | PHASE3 |
| NCT00642278 | COMPLETED | Diabetes Mellitus, Type II; Diabetes Mellitus, Non Insulin Dependent |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2008-04 | PHASE2 |
| NCT00631488 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2008-02 | PHASE2 |
| NCT00551590 | COMPLETED | Type 2 Diabetes Mellitus |
Ludwig-Maximilians - University of Munich |
2007-12 | PHASE1 |
| NCT00364377 | COMPLETED | Pre-diabetes |
Mayo Clinic |
2006-08 | PHASE4 |
| NCT00482729 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2007-06-19 | PHASE3 |
| NCT00716092 | COMPLETED | Diabetes Mellitus, Type 2 |
Boehringer Ingelheim |
2008-07 | PHASE2 |
| NCT00795275 | COMPLETED | Obesity |
University of Colorado, Denver |
2008-01 | |
| NCT00395343 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2006-12-11 | PHASE3 |
| NCT00971659 | COMPLETED | Type 2 Diabetes |
Profil Institut für Stoffwechselforschung GmbH |
2008-01 | PHASE1 |
| NCT00449930 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2007-03-01 | PHASE3 |
| NCT00832390 | COMPLETED | Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2007-02-14 | PHASE4 |
| NCT00397631 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2006-12-19 | PHASE3 |
| NCT00875394 | COMPLETED | Diabetes Mellitus, Non-Insulin-Dependent |
Merck Sharp & Dohme LLC |
2007-02-01 | PHASE3 |
| NCT00541229 | COMPLETED | Type 2 Diabetes |
Merck Sharp & Dohme LLC |
2007-08-24 | PHASE1 |
| NCT00501657 | COMPLETED | Gastroparesis; Diabetes Mellitus |
Royal Adelaide Hospital |
2007-07 | PHASE1 |
| NCT00484419 | COMPLETED | Type 2 Diabetes; Hyperlipidemia |
Daiichi Sankyo |
2007-05 | PHASE3 |
| NCT00305604 | COMPLETED | Type 2 Diabetes |
Merck Sharp & Dohme LLC |
2006-03-08 | PHASE3 |
| NCT00760344 | COMPLETED | Diabetes Mellitus |
Takeda |
2007-03 | PHASE2 |
| NCT00642798 | COMPLETED | Diabetes Mellitus Non-insulin-dependent |
Merck Sharp & Dohme LLC |
2008-03 | PHASE1 |
| NCT00929201 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2008-01 | PHASE1 |
| NCT00372060 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2006-08-21 | PHASE3 |
| NCT00363844 | COMPLETED | Type 2 Diabetes Mellitus |
Ono Pharmaceutical Co., Ltd. |
2006-08 | PHASE3 |
| NCT00363948 | COMPLETED | Type 2 Diabetes Mellitus |
Ono Pharmaceutical Co., Ltd. |
2006-08 | PHASE3 |
| NCT00363519 | COMPLETED | Type 2 Diabetes Mellitus |
Ono Pharmaceutical Co., Ltd. |
2006-08 | PHASE3 |
| NCT00961480 | COMPLETED | Type 2 Diabetes |
Merck Sharp & Dohme LLC |
2007-10 | PHASE1 |
| NCT00350779 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2006-06-12 | PHASE3 |
| NCT00477581 | COMPLETED | Type 2 Diabetes Mellitus |
AstraZeneca |
2007-05 | PHASE4 |
| NCT00411554 | COMPLETED | Diabetes Mellitus, Non-Insulin-Dependent |
Merck Sharp & Dohme LLC |
2007-01 | PHASE3 |
| NCT00337610 | COMPLETED | Type 2 Diabetes Mellitus (T2DM) |
Merck Sharp & Dohme LLC |
2006-06 | PHASE3 |
| NCT00541775 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2006-06 | PHASE3 |
| NCT00289848 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2006-03 | PHASE3 |
| NCT00095056 | COMPLETED | Diabetes Mellitus, Type 2; Chronic Renal Insufficiency |
Merck Sharp & Dohme LLC |
2004-10 | PHASE3 |
| NCT00106704 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2005-03 | PHASE3 |
| NCT00094770 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2004-09 | PHASE3 |
| NCT00127192 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2005-07 | PHASE2 |
| NCT00975052 | COMPLETED | Type 2 Diabetes |
Merck Sharp & Dohme LLC |
2006-01 | PHASE1 |
| NCT00758069 | COMPLETED | Diabetes Mellitus, Non-Insulin-Dependent |
Merck Sharp & Dohme LLC |
2005-07-03 | PHASE2 |
| NCT00961857 | COMPLETED | Type 2 Diabetes |
Merck Sharp & Dohme LLC |
2005-12-01 | PHASE1 |
| NCT00086502 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2004-06 | PHASE3 |
| NCT00094757 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2004-10-06 | PHASE3 |
| NCT00086515 | COMPLETED | Diabetes Mellitus, Type II |
Merck Sharp & Dohme LLC |
2004-06-30 | PHASE3 |
| NCT00087516 | COMPLETED | Diabetes Mellitus, Type 2 |
Merck Sharp & Dohme LLC |
2004-06 | PHASE3 |
| NCT00371007 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2004-06-01 | PHASE2 |
| NCT00944450 | COMPLETED | Type 2 Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2004-08 | PHASE1 |
| NCT00482079 | COMPLETED | Diabetes Mellitus, Type II |
Merck Sharp & Dohme LLC |
2003-05-13 | PHASE2 |
| NCT00481663 | COMPLETED | Type II Diabetes Mellitus |
Merck Sharp & Dohme LLC |
2003-08-19 | PHASE2 |
| NCT00696826 | COMPLETED | Liver Insufficiency |
Merck Sharp & Dohme LLC |
2004-04 | PHASE1 |
| NCT00418366 | COMPLETED | Renal Insufficiency; Hemodialysis |
Merck Sharp & Dohme LLC |
2003-01 | PHASE1 |
| NCT01054118 | COMPLETED | Diabetes Mellitus, Type 2 |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
2009-12 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-02-18)
Check the
Sitagliptin
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.